Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Heejoon Jang, Won Kim Clinical and Molecular Hepatology.2026; 32(2): e254. CrossRef
Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak Journal of Korean Medical Science.2026;[Epub] CrossRef
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Gut and Liver.2026; 20(4): 636. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Serum vitamin D and lean non-alcoholic fatty liver disease: a nonlinear ‘L-shaped’ association in a national cross-sectional study Gang Ma, Chongxiao Li, Erzhuo Xia, Jingbo Wang, Ying Han Annals of Medicine.2026;[Epub] CrossRef
Ceramide‐mediated mitochondrial dysfunction in nonobese nonalcoholic fatty liver disease: A regulatory role for serine palmitoyltransferase subunit 2 Li‐Jun Xue, Guang‐Yan Yao, Fei‐Fei Fan, Kai‐Min Li, Wen‐Ming Wu Journal of Cell Communication and Signaling.2026;[Epub] CrossRef
Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun Gut and Liver.2024; 18(2): 316. CrossRef
Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003–2018 Lurao Li, Xiawen Shu, Yun Yi, Chun Wang, Jianghui Li, Yang Ding, Jin Li, Ying Chang Lipids in Health and Disease.2024;[Epub] CrossRef
Obesity and risk for liver disease: a two-sample Mendelian randomisation study Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei British Journal of Nutrition.2024; 132(10): 1403. CrossRef
Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease Ioanna Aggeletopoulou, Maria Kalafateli, Efthymios P. Tsounis, Christos Triantos International Journal of Molecular Sciences.2023; 24(16): 12864. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liverrelated complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.
Citations
Citations to this article as recorded by
Attention-based graph neural network framework for non-invasive CAP score prediction in fatty liver disease via body modeling Ghasem Sadeghi Bajestani, Fatemeh Makhloughi, Ayoub Basham, Ebrahim Evazi, Mahdiyeh Razm Pour, Roohallah Alizadehsani, Farkhondeh Razmpour Physical and Engineering Sciences in Medicine.2026; 49(1): 183. CrossRef
AI-Based Models for Risk Prediction in MASLD: A Systematic Review Basile Njei, Yazan A. Al-Ajlouni, Samira Yaya Lemos, Derek Ugwendum, Nelvis Njei, Omar Al Ta’ani, Prince Ameyaw, Lea-Pearl Njei, Sarpong Boateng Digestive Diseases and Sciences.2026; 71(5): 1987. CrossRef
Steatosis-Associated Fibrosis Estimator Score in Asian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Kunhee Kim, Hye Won Lee, Jae Seung Lee, Mi Na Kim, Jun Yong Park Yonsei Medical Journal.2026; 67(2): 104. CrossRef
Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G World Journal of Hepatology.2026;[Epub] CrossRef
Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) Roberto Vettor, Maria Letizia Petroni, Idit Dotan, Gadi Lalazar, Martin Haluzík, C. Wendy Spearman, Joel A. Dave, Faisal Abaalkhail, Salah Abusnana, Ali Alshehri, Radan Bruha, Mariann Harangi, Ahmad Jazzar, Michał Kukla, Shiva Kumar, Vaia Lambadiari, Geor Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 213. CrossRef
Global, regional and national burden and trends of non-alcoholic fatty liver disease in women of reproductive age from 1990 to 2021: Insights from the Global burden of disease study 2021 Yi Yu, Chunxia Zhang, Zirong Liang, Xiang Wang, Jun Wang, Feihu Bai, Dekui Zhang, Yonggang Tian Indian Journal of Gastroenterology.2026;[Epub] CrossRef
A Cost–Utility Analysis of Two-Stage Screening Strategies Based on Waist-to-Height Ratio for Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in China Yunfei Liu, Tianyu Huang, Jiajia Dang, Shan Cai, Jiaxin Li, Ruolan Yang, Jiabin Zhang, Kaiheng Zhu, Ziyue Sun, Yang Yang, Yajie Wang, Bo Xi, Yi Song Healthcare.2026; 14(10): 1343. CrossRef
Imaging-based fibrosis assessment and risk stratification in MASLD Shunqin Jin, Tao Zhou, Dachuan Jin, Jiahao Xie, Guoping Sheng, Hongzhi Li, Guangming Li, Chuan Qin, Peng Gao Frontiers in Medicine.2026;[Epub] CrossRef
Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment Yusuf Kagzi, Abuzar Asif, Yanzhi Wang, Jacqueline Fischer, Sonu Dhillon Clinics and Research in Hepatology and Gastroenterology.2026; 50(7): 102879. CrossRef
CYP450 network shifts in MASLD/MASH: from pathogenesis to nutrition-informed modulation Sümeyye Koç, Sude Toydemir, Gökay Vardar, Gamze Nur Öter, Büşra Yusufoğlu The Journal of Nutritional Biochemistry.2026; 158: 110459. CrossRef
Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita Healthcare.2025; 13(7): 759. CrossRef
Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Hye Sun Lee, Young Hoon Youn, Su Jung Baik, Hana Lee, Joon Young Kim, Youngha Choi, Hyun Wook Chae Internal and Emergency Medicine.2025; 20(3): 785. CrossRef
Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study) Viswanathan Mohan, Shashank Joshi, Saket Kant, Altamash Shaikh, L. Sreenivasa Murthy, Banshi Saboo, Parminder Singh, Aravind R. Sosale, Debmalya Sanyal, G. Shanmugasundar, Santosh Kumar Singh, A. K. Pancholia, Sunetra Mondal, Rishi George, Ashok Jaiswal, Diabetes Therapy.2025; 16(7): 1435. CrossRef
Hepatic steatosis index for prediction of metabolic dysfunction‐associated steatotic liver disease (MASLD) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy Alpesh Goyal, Suraj Kubihal, Yashdeep Gupta, Shalimar, Devasenathipathy Kandasamy, Mani Kalaivani, Nikhil Tandon Diabetes, Obesity and Metabolism.2025; 27(10): 6018. CrossRef
Non-invasive detection of fibrosis in non-alcoholic fatty liver disease by serum microfibrillar-associated protein 4 and its correlation with FIB-4 and transient elastography Heba Abdel Rahman Eltony, Gamal Kasem, Radwa Mahmoud Elsharaby, Rehab Badawi, Eman M. Helal Egyptian Liver Journal.2025;[Epub] CrossRef
Evaluation of tri‐ponderal mass index in predicting metabolic associated fatty liver disease in obese children Yavuz Özer, Ersin Ulu, Emine Yurdakul Ertürk Pediatrics International.2025;[Epub] CrossRef
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study Dan Ye, Haifen Ma, Jingjing Zhou, Jiaofeng Wang, Jiaheng Shi, Jie Chen, Zhijun Bao, Xiaona Hu BMC Gastroenterology.2025;[Epub] CrossRef
Implementation of noninvasive liver disease screening tools in primary care Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura Korean Journal of Family Medicine.2025; 46(6): 381. CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
Validation of a screening panel for pediatric metabolic dysfunction–associated steatotic liver disease using metabolomics Helaina E. Huneault, Alasdair E. Gent, Catherine C. Cohen, Zhulin He, Zachery R. Jarrell, Rishikesan Kamaleswaran, Miriam B. Vos Hepatology Communications.2024;[Epub] CrossRef
Screening the General Population for Non-Alcoholic Fatty Liver Disease: Model Development and Validation Tanya Mohammadi, Babak Mohammadi Archives of Medical Research.2024; 55(3): 102987. CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
Evaluation of the ability of insulin resistance and lipid-related indices to predict the presence of NAFLD in obese adolescents Aylin Yetim, Memduh Şahin, İbrahim Kandemir, Betül Bulakçı, Melike Tuğrul Aksakal, Edanur Karapınar, Hayrettin Sever, Firdevs Baş Lipids in Health and Disease.2024;[Epub] CrossRef
Reference Range of Quantitative MRI Metrics Corrected T1 and Liver Fat Content in Children and Young Adults: Pooled Participant Analysis Elizabeth Shumbayawonda, Cayden Beyer, Benito de Celis Alonso, Silvia Hidalgo-Tobon, Briceida López-Martínez, Miguel Klunder-Klunder, América Liliana Miranda-Lora, E. Louise Thomas, Jimmy D. Bell, David J. Breen, Kamil Janowski, Maciej Pronicki, Wieslawa Children.2024; 11(10): 1230. CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective Cristina Maria Marginean, Denisa Pirscoveanu, Sergiu Marian Cazacu, Marian Sorin Popescu, Iulia Cristina Marginean, George Alexandru Iacob, Mihaela Popescu Gastroenterology Insights.2024; 15(4): 1028. CrossRef
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed Philipp Kasper, Münevver Demir, Hans-Michael Steffen Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Non-alcoholic fatty liver disease – a challenging health problem of the 21st century Anamaria Cozma-Petruţ, Lorena Filip , Doina Miere Dietetician.ro.2023; 2(2): 30. CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca Diagnostics.2023; 13(21): 3316. CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease Niketa Sharma, Swarupa Chakole, Bhushan Wandile Cureus.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Satoru Saito, Atsushi Nakajima Gut and Liver.2023; 17(6): 843. CrossRef
MASLD and aspartame: are new studies in the horizon? Consolato M. Sergi Frontiers in Medicine.2023;[Epub] CrossRef
Sessiz Epidemi: Metabolik Disfonksiyon İlişkili Karaciğer Yağlanması Hastalığının Önlenmesine ve Yönetilmesine Yönelik Güncel Yaklaşımlar Ferya ÇELİK, Merve YÜKSEL, Hicran BEKTAŞ Artuklu International Journal of Health Sciences.2023; 3(3): 343. CrossRef
Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono The Journal of Dermatology.2026; 53(2): 237. CrossRef
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan Katya Meridor, Stephanie R Harrison, Richard Parker, Chenchu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston Rheumatology.2026;[Epub] CrossRef
Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index Umut Bakay, Tugba Izci Duran, Ozge Sevil Karstarli Bakay, Rahime Ekmekcioglu Dermatology Practical & Conceptual.2026; 16(1): 6746. CrossRef
Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index Umut Bakay, Tugba Izci Duran, Ozge Sevil Karstarli Bakay, Rahime Ekmekcioglu Dermatology Practical & Conceptual.2026; 16(1): 6746. CrossRef
Primary Biliary Cholangitis: Immune Pathogenesis and Potential Targets for Therapy Mohamed Alsenbesy Current Hepatology Reports.2026;[Epub] CrossRef
Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease Wei Qiang Chng, Jake J. Liew, Choon Fong Liew, Mark Muthiah, Ming-Hua Zheng, Hazel H. Oon Frontiers in Immunology.2026;[Epub] CrossRef
Effects of Biologics on Fibrosis-4 Index in Patients with Psoriasis Takashi Morita, Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2025; 92(1): 88. CrossRef
Effects of Guselkumab on the FIB‐4 Index in Psoriasis Patients (EGIPT): A Three‐Year Study Edoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Claudia Paganini, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo The Journal of Dermatology.2025; 52(6): 1113. CrossRef
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma Baiyi Liu, Xiaoxiao Wang, Nan Wu, Feng Liu, Huiying Rao Current Medicinal Chemistry.2025; 32(23): 4786. CrossRef
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review Ilias D. Vachliotis, Stergios A. Polyzos Current Obesity Reports.2025;[Epub] CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study Saori Takamura, Souichiro Saito, Sora Sugai, Yuki Shiko, Takumi Yamaguchi, Yohei Kawasaki, Tomoo Fukuda The Journal of Dermatology.2025; 52(12): 1796. CrossRef
Dual roles of T cells in metabolic dysfunction–associated steatohepatitis pathogenesis and liver fibrosis: From inflammation to therapeutic targets Yijie Chen, Bei Jia, Xin Tong, Shengxia Yin, Wenjing Ni, Qianwen Zhao, Junping Shi, Jie Li Hepatology Communications.2025;[Epub] CrossRef
The role of interleukins-10 and -17 balance in the development of liver cirrhosis H. I. Yupatau, Viachaslau A. Pryshchepenka Vestnik of Vitebsk State Medical University.2025; 24(5): 30. CrossRef
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. Gottlieb Journal of the American Academy of Dermatology.2024; 91(2): 281. CrossRef
Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not interleukin‐17 inhibitors Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Hideaki Uchida, Chika Chijiwa, Yoshiki Okada, Saori Azuma, Mayumi Nagata, Shota Egawa, Azusa Hiura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa The Journal of Dermatology.2024; 51(9): 1216. CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
Evolution of FIB-4 score in SpA and PsA patients taking anti-TNF or anti-IL17 Frank Verhoeven, Clément Prati, Vincent Di Martino, Thierry Thevenot, Céline Demougeot, Daniel Wendling, Delphine Weil-Verhoeven Joint Bone Spine.2024; 91(6): 105763. CrossRef
Application of graph theory in liver research: A review Xumei Hu, Longyu Sun, Rencheng Zheng, Xueqin Xia, Meng Liu, Weibo Chen, Xinyu Zhang, Chengyan Wang Portal Hypertension & Cirrhosis.2024; 3(4): 234. CrossRef
Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2024; 91(6): 534. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao Frontiers in Immunology.2023;[Epub] CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit Frontiers in Medicine.2022;[Epub] CrossRef
Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort Dalia E. Sherief, Hadeer Hamdy Shehata, Nahla Nosair, Amira A. A. Othman, Mohamed W. Saleh, Emad Sadaka, Rasha Elgamal BMC Gastroenterology.2026;[Epub] CrossRef
Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease Andrei Sorop, Alina-Veronica Ghionescu, Diana Larisa Ancuța, Maria-Gabriela Croitoru, Cristin Coman, Daniela Lixandru, Simona Olimpia Dima Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim Cancers.2025; 17(4): 566. CrossRef
Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer Tagari Samanta, Jun Hyoung Park, Benny Abraham Kaipparettu Cancers.2025; 17(5): 844. CrossRef
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050 Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients Hamdan S. AlGhamdi, Nawaf M. AlYahya, Ibrahim M. Bahabri, Majed A. Al Ashaikh, Abdulrahman K. Habib, Abdulaziz A. AlAhmary, Nuha Al Ajlan, Abdulrahman I. AlAbdulgader, Abduljaleel M. Alalwan, Faisal M. Sanai Saudi Journal of Gastroenterology.2025; 31(6): 356. CrossRef
Non-Viral Hepatocellular Carcinoma with Normal Alpha-Fetoprotein but Elevated CA19-9 in an Older Patient with Obesity: A Case Report Seung Hun Lee, Mi Soo Kim, Jeong Gyu Lee Korean Journal of Geriatrics & Gerontology.2025; 26(3): 147. CrossRef
Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma Alok Raghav, Goo Bo Jeong Cells.2024; 13(7): 638. CrossRef
Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes Jinyue Tian, Jiao Meng, Zhenkun Yang, Li Song, Xinyi Jiang, Jian Zou Frontiers in Immunology.2024;[Epub] CrossRef
Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels Zhan Lin, Mei Gan, Xiangping Wang, Zhonghua Su Reproductive Health.2024;[Epub] CrossRef
Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil Cureus.2024;[Epub] CrossRef
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Seren M. Gedallovich, Paul Y. Kwo Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Occurrence of Liver Cancer in People without Traditional Risk Factors Junho Choi, Joohyun Park, Jae Kwang Lee, Kyunghee Cho Korean Journal of Clinical Geriatrics.2023; 24(1): 41. CrossRef
The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics K. P. Divya, Parneet Hari, Navjot Kanwar, Navita Aggarwal, Preeti Singh Dhoat, Lu Liu, Abhinav Kanwal, Shailendra Pratap Singh, Jiong Yu Advanced Gut & Microbiome Research.2023; 2023: 1. CrossRef
Bursatella leachii Purple Ink Secretion Concentrate Exerts Cytotoxic Properties against Human Hepatocarcinoma Cell Line (HepG2): In Vitro and In Silico Studies Zeyad I. Alehaideb, Anuradha Venkatraman, Mahadev Kokane, Syed Ali Mohamed, Saranya Rameshbabu, Rasha S. Suliman, Sahar S. Alghamdi, Hamad Al-Eidi, Bandar Alghanem, Maha-Hamadien Abdulla, Sabine Matou-Nasri Molecules.2022; 27(3): 826. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study Mengmeng Song, Tong Liu, Hai Liu, Qi Zhang, Qingsong Zhang, Yiming Wang, Xiangming Ma, Liying Cao, Hanping Shi BMC Cancer.2022;[Epub] CrossRef
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease Joo Hyun Oh, Je Hee Lee, Min Seok Cho, Hyeree Kim, Jongsik Chun, Joon Hyeok Lee, Yeup Yoon, Wonseok Kang Nutrients.2021; 13(3): 1013. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.
Citations
Citations to this article as recorded by
Boala ficatului gras metabolic asociat și patologia cardiovasculară – conexiune cu dublă cauzalitate Irina Cabac-Pogorevici, Inessa Jitari, Dmitri Savca, Valeriu Revenco Public Health Economy and Management in Medicine.2026; (4(97)): 25. CrossRef
Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH) Emily Wood, Rukayat Akande, Iqra Iqbal, Stewart G. Albert Diabetes, Obesity and Metabolism.2026; 28(2): 1266. CrossRef
Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis Xin Shao, Jun You, Hui Zhang, XianHong Jiang Frontiers in Endocrinology.2026;[Epub] CrossRef
Exploring Therapeutic Potential of Hydrotropic Solid Dispersions of Hesperidin and Naringenin for the Management of Diabetes and Obesity Bhawna Arora, Viney Lather, Mallikarjuna Bandrehalli Pathalingappa, Amarjeet Singh, Ramanpreet Walia Current Drug Therapy.2026; 21(2): 259. CrossRef
Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes A.M. Urbanovych, N.Ya. Sidelnyk, O.Z. Lishchuk INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(3): 340. CrossRef
Multifaceted therapeutic potential of saponins in type 2 diabetes mellitus: mechanisms targeting insulin resistance and diabetic complications Yuan Yuan, Ke-Ying Shou, Si-Qi Wu, Jing-Yu Zhao, Yao Liu, Ya-Jun Wang, Hua-Song Luo, Wen-Ting Dai Frontiers in Pharmacology.2026;[Epub] CrossRef
Fibrocalculous Pancreatic Diabetes: Changing Clinical Spectrum and Glycaemic Response to Pioglitazone Don David, Manjunath Goroshi, Vanishri Ganakumar, Vikrant Ghatnatti Indian Journal of Endocrinology and Metabolism.2026; 30(3): 223. CrossRef
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Journal of Clinical Medicine.2025; 14(2): 428. CrossRef
Deciphering significances of autophagy in the development and metabolism of adipose tissue Zitao Liu, Haoyuan Peng, Pengfei Liu, Feiyi Duan, Yutian Yang, Pengkun Li, Zhihao Li, Jiaoyan Wu, Jiayi Chang, Dandan Shang, Qiwen Tian, Jiawei Zhang, Yucheng Xie, Zhenzhen Liu, Yang An Experimental Cell Research.2025; 446(2): 114478. CrossRef
Pengaruh Ekstrak Etanol Daging Buah Pala (Myristica Fragrans Houtt) Pada Histopatologi Jantung Tikus Wistar Hiperglikemik Amran Nur, Ermalyanti Fiskia, Muhammad Fakhrur Rajih Hi Yusuf, Muhammad Zulfian A. Disi, Nita Mursin Journal of Pharmaceutical and Sciences.2025; : 1469. CrossRef
Cumulative Hepatoprotective, Antihyperlipidemic and Antioxidant Effects of Methanolic Seeds Extract of Citrullus lanatus, Cucumis melo, Cucumis sativus, and Cucurbita maxima With GC–MS Profile Hina Ilyas, Sadia Ghousia Baig, Sana Sarfaraz, Farzana Sadaf, Afshan Siddiq, Ali Asgher, Muhammad Osama, Qudsia Basri, Calvin R Wei Food Science & Nutrition.2025;[Epub] CrossRef
The role of glycolysis in MASLD development: Pathogenesis and therapeutic strategies Yidan Shang, Qinmei Sun, Xin Xin, Zhuoyuan Wang, Siting Gao, Rutao Lin, Yiyang Hu, Xiaoning Wang, Qin Feng Pharmacological Research.2025; 221: 107990. CrossRef
Herbal Combination of Angelica gigas, Zingiber officinale, and Aconitum carmichaeli Alleviates High Fat Diet‐Induced Non‐Alcoholic Fatty Liver Disease in Mice Through NRF2‐Mediated Regulation of Adipogenesis and Non‐Shivering Thermogenesis Harim Kim, Hye‐Lin Kim, Mina Boo, Hyunyoung Choi, Jaehyun Han, Seunghyun Nam, So Jung Kang, Jae Kyeom Kim, Yohan Han, Ji Hoon Jung, Woojin Kim, Kwan‐Il Kim, Jae‐Young Um, Jinbong Park, Leo E. Otterbein, Hyo In Kim, Seong‐Gyu Ko Food Science & Nutrition.2025;[Epub] CrossRef
Treatment with a new barbituric acid derivative suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice Fat-Moon Suk, Fang-Yu Hsu, Ming-Hua Hsu, Wan-Chun Chiu, Cheng-Chieh Fang, Tzu-Lang Chen, Yi-Jen Liao Life Sciences.2024; 336: 122327. CrossRef
Metabolic Associated Fatty Liver Disease in Children and Adolescents:
Mechanisms of a Silent Epidemic and Therapeutic Options Antonella Mosca, Luca Della Volpe, Maria Rita Sartorelli, Donatella Comparcola, Silvio Veraldi, Anna Alisi, Giuseppe Maggiore Current Pediatric Reviews.2024; 20(3): 296. CrossRef
Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi Expert Opinion on Pharmacotherapy.2024; 25(7): 925. CrossRef
The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi Annals of Military and Health Sciences Research.2024;[Epub] CrossRef
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus Monika Bhardwaj, Papiya Mitra Mazumder Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 8421. CrossRef
NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors Nutan Sharma, Lakhwinder Singh, Aditya Sharma, Ajay Kumar, Dinesh Mahajan Pharmacological Research.2024; 208: 107375. CrossRef
Regulation mechanism of endoplasmic reticulum stress on metabolic enzymes in liver diseases Shaojun Zhou, Kaiwen Cheng, Yi Peng, Yuxi Liu, Qingqing Hu, Su Zeng, Xuchen Qi, Lushan Yu Pharmacological Research.2024; 207: 107332. CrossRef
Effects of Propolis Consumption on Glycemic Indices and Liver Enzymes in Adults: A Grading of Recommendations Assessment, Development, and Valuation-assessed Systematic Review and Dose-Response Meta-analysis Shaghayegh Adeli, Mahsa Maroofi, Fatemeh Pourteymour Fard Tabrizi, Beitullah Alipour, Marzieh Heidari, Mahdi Vajdi, Mahdieh Abbasalizad-Farhangi Clinical Therapeutics.2024; 46(9): e6. CrossRef
Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis N.M. Protas, I.O. Kostitska, M.V. Bielinskyi INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(5): 375. CrossRef
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress Erika T. Minetti, Naomi M. Hamburg, Reiko Matsui Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef
The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial Zeinab Anwar ElKabbany, Eman Abdel Rahman Ismail, Eman Tawfik Hamed, Nancy Samir Elbarbary Diabetes, Obesity and Metabolism.2024; 26(12): 5857. CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up Qi‐En Shen, Chengfu Xu Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1662. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
Development and prognosis of hepatocellular carcinoma in patients with diabetes Takuma Nakatsuka, Ryosuke Tateishi Clinical and Molecular Hepatology.2023; 29(1): 51. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Linalool Mitigated High-Fat Diet–Induced Non-alcoholic Fatty Liver Disease by Regulating the Intestinal-Hepatic Axis via TGF-β/NF-kB/TLR4/ZO-1 Pathway Tamilmani Periyasamy, V. V. Sathibabu Uddandrao, Chandrasekaran Ponnusamy, Saravanan Ganapathy, Sethumathi Ponnusamy Pudhupalayam, Sengottuvelu Singaravel, Ponmurugan Ponnusamy, Jagadeesan Ramasamy, Kalaivani Aiyasamy, Vadivukkarasi Sasikumar Revista Brasileira de Farmacognosia.2023; 33(3): 617. CrossRef
The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis Ki-Kwang Oh, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Byeong-Hyun Min, Ji-Ye Hyun, Jung-A Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Dong Joon Kim, Ki-Tae Suk Artificial Cells, Nanomedicine, and Biotechnology.2023; 51(1): 217. CrossRef
Malattia grassa del fegato: tra fattori ambientali e predisposizione genetica Antonella Mosca, Giuseppe Maggiore Medico e Bambino.2023; 42(6): 355. CrossRef
E4orf1 improves adipose tissue-specific metabolic risk factors and indicators of cognition function in a mouse model of Alzheimer’s disease Md Shahjalal Hossain Khan, Marleigh Hefner, Arubala Reddy, Nikhil V. Dhurandhar, Vijay Hegde Nutrition & Diabetes.2023;[Epub] CrossRef
Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan Chin-Hsiao Tseng Cancers.2023; 15(17): 4276. CrossRef
Carbon Dots as Potential Therapeutic Agents for Treating Non-Alcoholic Fatty Liver Disease and Associated Inflammatory Bone Loss Lei Huang, Qinzhu Bai, Zhuoran Wang, Xu Zhang, Kexuan Liu, Jing Cui, Liuyi Du, Shuchen Liu, Yunhe Fu, Huan Wang, Daowei Li, Hongchen Sun Bioconjugate Chemistry.2023; 34(9): 1704. CrossRef
Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease Mengran Shi, Hao Zhang, Wei Wang, Xiao Zhang, Jiawei Liu, Qixian Wang, Yuan Wang, Chunlin Zhang, Xiaoqin Guo, Qiao Qiao, Chun Cui, Jing Xu, Jian Wang Journal of Diabetes and its Complications.2023; 37(10): 108610. CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang Liver International.2022; 42(2): 320. CrossRef
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee Diabetes, Obesity and Metabolism.2022; 24(6): 1105. CrossRef
Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis Tea Omanovic Kolaric, Tomislav Kizivat, Vjera Mihaljevic, Milorad Zjalic, Ines Bilic-Curcic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, George Y. Wu, Martina Smolic Current Issues in Molecular Biology.2022; 44(8): 3465. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist Shasta Tall Bull, Wesley Nuffer, Jennifer M. Trujillo Journal of Diabetes and its Complications.2022; 36(12): 108332. CrossRef
Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients Ziyin Zhang, Lu Zhang, Wangyan Jiang, Tingting Du, Gang Yuan Cardiovascular Diabetology.2022;[Epub] CrossRef
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee Journal of the Chinese Medical Association.2022; 85(12): 1109. CrossRef
Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine – a case study of diabetes and nonalcoholic fatty liver disease Yang Bao, Xiao Han, Da Liu, Zhaolin Tan, Yongzhi Deng Frontiers in Immunology.2022;[Epub] CrossRef
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once? Ji Cheol Bae Endocrinology and Metabolism.2022; 37(6): 858. CrossRef
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis Narjes Nasiri-Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, Ioannis Kyrou, Christos S. Mantzoros, Georgios Kyriakopoulos, Antonios Chatzigeorgiou, Vassiliki Kalotychou, Manpal S. Randeva, Kamaljit Chatha, Konstantinos Kontzoglou, Gregory Kaltsas, Athana International Journal of Molecular Sciences.2021; 22(2): 818. CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment Sook Jung Lee, Byung-Wan Lee The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee Clinical and Molecular Hepatology.2021; 27(2): 257. CrossRef
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis Jingxuan Lian, Jianfang Fu Frontiers in Endocrinology.2021;[Epub] CrossRef
Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives Christina-Maria Flessa, Ioannis Kyrou, Narjes Nasiri-Ansari, Gregory Kaltsas, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva Current Obesity Reports.2021; 10(2): 134. CrossRef
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis Jingxuan Lian, Jianfang Fu Frontiers in Endocrinology.2021;[Epub] CrossRef
Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome Stewart G. Albert, Emily M. Wood Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102232. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska International Journal of Molecular Sciences.2021; 22(21): 11513. CrossRef
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease Yuting Ma, Chengxia Kan, Hongyan Qiu, Yongping Liu, Ningning Hou, Fang Han, Junfeng Shi, Xiaodong Sun Frontiers in Pharmacology.2021;[Epub] CrossRef
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”? Dimitrios Patoulias, Michael Doumas Clinical and Molecular Hepatology.2020; 26(4): 582. CrossRef
First
Prev
